Filtered By:
Condition: Atrial Fibrillation
Countries: Japan Health
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 333 results found since Jan 2013.
Impact of B-Type Natriuretic Peptide Level on Risk Stratification of Thromboembolism and Death in Patients With Nonvalvular Atrial Fibrillation - The Hokuriku-Plus AF Registry.
CONCLUSIONS: In a real-world cohort of Japanese NVAF patients, high BNP was significantly associated with TE and death. Plasma BNP might be a useful biomarker for these adverse clinical events.
PMID: 29491320 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 1, 2018 Category: Cardiology Authors: Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, Konno T, Nakanishi C, Tada H, Nagata Y, Teramoto R, Tanaka Y, Kawashiri MA, Yamagishi M, Hokuriku-Plus AF Registry Investigators Tags: Circ J Source Type: research
Registry of Japanese patients with atrial fibrillation focused on anticoagulant therapy in the new era: The RAFFINE registry study design and baseline characteristics.
CONCLUSION: The RAFFINE registry at baseline described the current status of anticoagulation therapy in Japan and long-term follow-up data will identify how outcomes vary between stratified groups in patients with AF in the DOAC era (UMIN Clinical Trials Registry UMIN000009617).
PMID: 29502944 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 1, 2018 Category: Cardiology Authors: Miyazaki S, Miyauchi K, Hayashi H, Tanaka R, Nojiri S, Miyazaki T, Sumiyoshi M, Suwa S, Nakazato Y, Urabe T, Hattori N, Daida H Tags: J Cardiol Source Type: research
Sex Differences in Long-Term Clinical Outcomes in Patients With Atrial Fibrillation Undergoing Coronary Stent Implantation.
CONCLUSIONS: Among patients with concomitant AF and coronary stenting, there were no significant differences in the adjusted 3-year risks for all-cause death, myocardial infarction, and stroke between men and women. However, women as compared with men were associated with excess adjusted risk for major bleeding.
PMID: 29593146 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 29, 2018 Category: Cardiology Authors: Matsumura-Nakano Y, Shiomi H, Morimoto T, Shizuta S, Yamaji K, Watanabe H, Yoshikawa Y, Taniguchi T, Kawaji T, Natsuaki M, Akasaka T, Hanaoka K, Kadota K, Kozuma K, Tanabe K, Nakagawa Y, Muramatsu T, Morino Y, Ando K, Kimura T Tags: Circ J Source Type: research
Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study.
CONCLUSIONS: Findings suggest treatment satisfaction may improve in Japanese NVAF patients after a switch from warfarin to rivaroxaban. Higher treatment satisfaction may translate into improved treatment adherence, which is critical for the long-term prevention of stroke.
PMID: 30067119 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 3, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 30, 2018 Category: Cardiology Source Type: research
Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation - The Fushimi AF Registry.
CONCLUSIONS: In Japanese AF patients receiving OAC, the prevalence of combination therapy decreased, with the proportion of NOAC use increasing in 2011-2017. Many patients, however, received off-label NOAC under-dosing, especially in the combination therapy group. Patients with combination therapy had higher incidences of major bleeding as well as stroke/systemic embolism, compared with OAC monotherapy.
PMID: 30381701 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 31, 2018 Category: Cardiology Authors: Masunaga N, Abe M, Ogawa H, Aono Y, Ikeda S, Doi K, An Y, Ishii M, Iguchi M, Esato M, Tsuji H, Wada H, Hasegawa K, Lip GYH, Akao M, Fushimi AF Registry Investigators Tags: Circ J Source Type: research
Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry.
CONCLUSIONS: Nearly half of the NOAC dose reductions in our registry were deemed "non-standardized," which were seen mostly in patients at significant risk for ischemic stroke. The physician's apprehension regarding excessive bleeding under NOAC use should be appropriately balanced with concern for an increased risk of embolic events.
PMID: 30487057 [PubMed - in process]
Source: Journal of Cardiology - December 1, 2018 Category: Cardiology Authors: Ono T, Ikemura N, Kimura T, Ueda I, Tanaka H, Tokuda H, Yajima N, Matsumura K, Suzuki M, Fukuda K, Kohsaka S, Takatsuki S Tags: J Cardiol Source Type: research
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance.
CONCLUSIONS: The present results are indicative of the favorable benefit-risk profile of dabigatran in Japanese clinical practice. Dabigatran dose was not independently associated with thromboembolic and bleeding events in Japanese NVAF patients.
PMID: 30737182 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 5, 2019 Category: Cardiology Authors: Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Taniguchi A, Fukaya T, J-Dabigation Surveillance Investigators Tags: J Cardiol Source Type: research
Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
ConclusionsIn Japan, physicians who attempt stroke prevention in patients with atrial fibrillation choose appropriate anticoagulant treatment, taking into consideration the individual patient backgrounds as well as the features of each antithrombotic agent.Trial RegistrationClinicalTrials.gov Identifier, NCT01491178 and University Hospital Medical Information Network (UMIN) Clinical Trial Registry Identifier, UMIN000009644.FundingNippon Boehringer Ingelheim Co., Ltd.Plain Language SummaryPlain language summary available for this article.
Source: Cardiology and Therapy - February 11, 2019 Category: Cardiology Source Type: research
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
CONCLUSIONS: Real-world outcomes of the XAPASS showed incidence rates of major bleeding and thromboembolic events, suggesting that rivaroxaban is safe and effective in Japanese daily clinical practice (Clinicaltrials.gov: NCT01582737).
PMID: 30745002 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 7, 2019 Category: Cardiology Authors: Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Ohashi Y, Okayama Y, Sunaya T, Yamanaka S Tags: J Cardiol Source Type: research
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance.
CONCLUSIONS: The present results are indicative of the favorable benefit-risk profile of dabigatran in Japanese clinical practice. Dabigatran dose was not independently associated with thromboembolic and bleeding events in Japanese NVAF patients.
PMID: 30871851 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 10, 2019 Category: Cardiology Authors: Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Taniguchi A, Fukaya T, J-Dabigatran Surveillance Investigators Tags: J Cardiol Source Type: research
University hospitals, general hospitals, private clinics: Place-based differences in patient characteristics and outcomes of AF-A SAKURA AF Registry Substudy.
CONCLUSIONS: Adverse clinical events at small to large hospitals appear to be higher than those at private clinics, suggesting that careful attention for preventing stroke/SE and cardiovascular events should be paid to patients at a university or general hospital.
PMID: 31253524 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - June 24, 2019 Category: Cardiology Authors: Kogawa R, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Nishida T, Matsumoto M, Kojima T, Hanada S, Nomoto K, Sonoda K, Arima K, Takahashi F, Kotani T, Ohkubo K, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, Tags: J Cardiol Source Type: research
Risk Stratification of Cardiovascular Events in Very Elderly Patients with Known or Suspected Coronary Artery Disease Who had Normal Single-photon Emission Computed Tomographic Myocardial Perfusion Imaging Findings.
Conclusion The MCV event rate was high in very elderly patients despite their normal SPECT MPI findings at baseline. Therefore, very elderly patients with multivariate risks should be carefully followed to avoid a poor prognosis.
PMID: 31366795 [PubMed - as supplied by publisher]
Source: Internal Medicine - August 3, 2019 Category: Internal Medicine Tags: Intern Med Source Type: research
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
AbstractThe approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial fibrillation (NVAF) in Japan is 15 mg once daily (od) in patients whose creatinine clearance is ≥ 50 mL/min, but recent real-world studies have demonstrated that these patients often received less than the recommended dose due to bleeding concerns. The effect of under-dosing on safety and effectiveness outcomes remains uncle ar. We used 1-year follow-up data from the XAPASS, a real-world Japanese prospective, single-arm, observational study. Of the 11,308 patients, 6521 patients who completed a 1-year follow-up and ha...
Source: Journal of Thrombosis and Thrombolysis - August 19, 2019 Category: Hematology Source Type: research
Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: A retrospective observational study.
CONCLUSIONS: In a current real-world setting in Japan, warfarin was the most commonly used treatment in AF patients with bioprosthetic valves, but there was an increasing trend of DOAC-treated patients. Further investigations are needed to confirm the efficacy and safety of DOAC in patients with bioprosthetic valves.
PMID: 32156512 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 6, 2020 Category: Cardiology Authors: Izumi C, Miyake M, Amano M, Kitai T, Obayashi Y, Takegami M, Kimura T, Sugio K, Matsumoto T, Nishimura K, Furukawa Y Tags: J Cardiol Source Type: research
